Predictions
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€85.44
24.06.23
24.06.23
€100.00
31.07.25
31.07.25
-18.52%
24.05.24
24.05.24
Could be very worthwhile Investment >20% year
AbbVie Inc.
Start price
Target price
Perf. (%)
€126.10
17.06.23
17.06.23
-
17.06.24
17.06.24
19.25%
24.05.24
24.05.24
Could be worthwhile Investment >10% per year
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€307.95
30.05.23
30.05.23
€356.18
30.05.24
30.05.24
36.78%
24.05.24
24.05.24
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€307.95
30.05.23
30.05.23
€356.18
30.05.24
30.05.24
36.78%
24.05.24
24.05.24
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€307.95
30.05.23
30.05.23
€356.18
30.05.24
30.05.24
36.78%
24.05.24
24.05.24
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€397.00
24.05.23
24.05.23
€464.75
24.05.24
24.05.24
88.53%
24.05.24
24.05.24
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€397.00
24.05.23
24.05.23
€462.89
24.05.24
24.05.24
88.53%
24.05.24
24.05.24
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€196.52
08.01.22
08.01.22
€915.00
14.01.27
14.01.27
114.33%
24.05.24
24.05.24
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
ROE higher than 15% per year
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€196.52
08.01.22
08.01.22
€915.00
14.01.27
14.01.27
114.33%
24.05.24
24.05.24
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
ROE higher than 15% per year
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€196.52
08.01.22
08.01.22
€915.00
14.01.27
14.01.27
114.33%
24.05.24
24.05.24
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
ROE higher than 15% per year
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€70.48
30.09.16
30.09.16
€98.00
08.09.26
08.09.26
10.14%
24.05.24
24.05.24
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€70.48
30.09.16
30.09.16
€98.00
08.09.26
08.09.26
10.14%
24.05.24
24.05.24
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€70.48
30.09.16
30.09.16
€98.00
08.09.26
08.09.26
10.14%
24.05.24
24.05.24
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued